A phase 4, open-label study to evaluate the safety and immunogenicity of DTaP5-HBV-IPV-Hib in children previously vaccinated with DTaP2-HBV-IPV-Hib or DTaP5-HBV-IPV-Hib (V419-016)

A phase 4, open-label study to evaluate the safety and immunogenicity of DTaP5-HBV-IPV-Hib in children previously vaccinated with DTaP2-HBV-IPV-Hib or DTaP5-HBV-IPV-Hib (V419-016)

ABSTRACTDTaP5-HBV-IPV-Hib (Vaxelis®) is a hexavalent combination vaccine (HV) indicated in infants and toddlers for the prevention of diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, and invasive disease due to Haemophilus influenzae type b. Switching between HVs during the childhood vacc...

Full description

Bibliographic Details
Main Authors: Andrea Guerra, Claudio Costantino, Federico Martinon-Torres, Soeren Westerholt, Courtney Lambeth, Ziqiang Chen, Jessie Lumley, Tomas Marcek, David Johnson, Marissa Wilck
Format: Article
Language:English
Published: Taylor & Francis Group 2024-12-01
Series:Human Vaccines & Immunotherapeutics
Subjects:
Vaxelis
hexavalent combination vaccine
interchangeability
vaccine
safety
immunogenicity
Online Access:https://www.tandfonline.com/doi/10.1080/21645515.2024.2310900

Internet

https://www.tandfonline.com/doi/10.1080/21645515.2024.2310900

Similar Items